In real-world use, the recombinant shingles vaccine prevents about 73% of cases of herpes zoster ophthalmicus — a serious eye infection — in adults aged 50 and older.

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.